Cystinuria

1. Executive Overview: Understanding Cystinuria

Cystinuria (ICD-10: E72.01) is a rare, autosomal recessive genetic disorder characterized by the impaired renal tubular reabsorption of the dibasic amino acids: cystine, ornithine, lysine, and arginine. While the condition is systemic in its genetic origin, its clinical morbidity is almost exclusively confined to the urinary tract. The hallmark of cystinuria is the development of recurrent nephrolithiasis (kidney stones) due to the poor solubility of cystine in acidic urine.

Unlike glomerular diseases, which involve the filtration barrier of the nephron, cystinuria is fundamentally a tubular transport pathology. It arises from mutations in the SLC3A1 or SLC7A9 genes, which encode the subunits of the cystine transporter protein in the proximal convoluted tubule. If left unmanaged, the chronic mechanical trauma of stone passage and obstructive uropathy can lead to significant renal parenchyma damage, culminating in chronic kidney disease (CKD).

2. Pathophysiology, Etiology, and Risk Factors

The Molecular Mechanism

The proximal tubule is responsible for reabsorbing approximately 98% of filtered cystine. In healthy individuals, the rBAT protein (encoded by SLC3A1) and the b0,+AT protein (encoded by SLC7A9) form a complex that facilitates the transport of cystine from the tubular lumen back into the cell.

In cystinuria, this transport system fails. Consequently, massive amounts of cystine are excreted into the urine. Because cystine is highly insoluble at physiological urinary pH (below 7.0), it precipitates out of solution to form hexagonal, crystalline stones.

Glomerular vs. Tubular Distinction

It is critical for clinicians to differentiate cystinuria from glomerular pathologies.
* Glomerular Pathology: Characterized by hematuria, proteinuria (often nephrotic range), and decreased eGFR due to filtration barrier damage (e.g., FSGS, membranous nephropathy).
* Tubular Pathology (Cystinuria): Characterized by selective aminoaciduria. The glomerular filtration rate (GFR) remains normal unless secondary obstructive uropathy or interstitial fibrosis from recurrent stone disease occurs.

Risk Factors for Progression

• Genetic Heterogeneity: Patients with SLC3A1 mutations (Type I) often show complete absence of transport, while SLC7A9 mutations (Type non-I) may show residual transport activity.
• Urine pH: A urinary pH < 7.0 is the primary risk factor for crystallization.
• Hydration Status: Low urine volume leads to supersaturation of cystine.

3. Signs, Symptoms, and Clinical Presentation

The clinical presentation of cystinuria is dominated by the consequences of urolithiasis.

• Renal Colic: Acute, severe flank pain radiating to the groin, often accompanied by nausea and vomiting.
• Gross/Microscopic Hematuria: Resulting from the mucosal abrasion caused by stone movement.
• Obstructive Uropathy: If stones are large or branched (staghorn calculi), they may cause hydronephrosis.
• Systemic Consequences: Chronic obstruction can lead to "Silent" CKD. As obstruction persists, the kidney undergoes pressure atrophy, leading to a rise in serum creatinine and a decline in eGFR.
• CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder): In advanced cases of cystinuria-induced nephropathy, secondary hyperparathyroidism and bone mineral density loss may occur due to impaired renal handling of phosphorus and vitamin D activation.

4. Diagnostic Evaluation and Workup

Diagnostic accuracy is paramount to prevent the transition from a manageable metabolic disorder to end-stage renal disease (ESRD).

Laboratory Assays

1. Urinalysis: Look for the pathognomonic hexagonal crystals on microscopy.
2. 24-Hour Urine Collection: The gold standard for quantification. A cystine excretion > 250–300 mg/day is diagnostic.
3. Serum Creatinine and eGFR: Essential for KDIGO staging. A baseline creatinine is necessary to monitor for potential renal scarring.
4. Nitroprusside Cyanide Test: A qualitative screening tool that turns purple in the presence of high cystine levels.

Imaging Modalities

• Non-contrast CT (CT KUB): The modality of choice. Cystine stones have a lower Hounsfield unit density than calcium oxalate stones but are still radio-opaque.
• Renal Ultrasound: Used for monitoring hydronephrosis and tracking stone size without ionizing radiation.

Biopsy Indications

Renal biopsy is not indicated for the diagnosis of cystinuria itself. However, if a patient presents with unexplained proteinuria or a rapid decline in eGFR that does not correlate with stone burden, a biopsy may be indicated to rule out co-morbid glomerular disease or chronic interstitial nephritis.

5. Therapeutic Interventions

Management is centered on increasing the solubility of cystine and reducing the urinary concentration of the amino acid.

Lifestyle and Medical Nutrition Therapy

• Hyperhydration: The most critical intervention. Patients should maintain a urine output of > 3 liters per day to keep the cystine concentration below its solubility limit.
• Alkalinization: Use of potassium citrate or sodium bicarbonate to maintain a urinary pH between 7.0 and 7.5. This significantly increases cystine solubility.
• Sodium Restriction: High sodium intake increases cystine excretion. A low-sodium diet (< 2g/day) is highly recommended.

Pharmacotherapy

• Thiol-containing agents: If hydration and alkalinization fail, Tiopronin or D-penicillamine are used. These drugs break the disulfide bond of cystine, creating a more soluble complex (cysteine-drug complex).
• Monitoring: Regular monitoring of eGFR and serum creatinine is mandatory to ensure these medications are not causing secondary renal toxicity.

Surgical Intervention

• ESWL (Extracorporeal Shock Wave Lithotripsy): Generally less effective for cystine stones due to their density and toughness.
• PCNL (Percutaneous Nephrolithotomy): The preferred treatment for large, staghorn, or complex cystine calculi.
• Ureteroscopy: Used for smaller, symptomatic stones.

6. Frequently Asked Questions (FAQ)

1. Is cystinuria a form of kidney failure?
No, it is a genetic metabolic disorder. However, if recurrent stones cause chronic obstruction and infection, it can lead to CKD and eventually kidney failure.

2. Can cystinuria be cured?
There is no "cure" for the underlying genetic defect. Treatment focuses on preventing stone formation through diet, hydration, and medication.

3. What is the difference between nephrotic and nephritic syndrome in cystinuria?
Cystinuria is neither. Nephrotic/nephritic syndromes are glomerular. Cystinuria is a tubular disorder; however, secondary damage can lead to renal failure.

4. How often should I check my eGFR?
Patients with frequent stones or evidence of renal scarring should have their eGFR and creatinine monitored at least every 6 months to 1 year.

5. Why are cystine stones harder to treat than other stones?
Cystine stones are resistant to lithotripsy (shock waves) and recur very rapidly, making long-term medical compliance essential.

6. Is a kidney biopsy necessary for diagnosis?
No. Diagnosis is confirmed through 24-hour urine collection and genetic testing. Biopsy is only for secondary complications.

7. Does diet play a major role in management?
Yes. A low-sodium and low-methionine (the precursor to cystine) diet is vital for reducing cystine excretion.

8. What does a "hexagonal crystal" look like?
Under a microscope, they appear as flat, colorless, six-sided plates. They are highly specific for cystinuria.

9. Can cystinuria cause high blood pressure?
Yes. If the condition leads to CKD, hypertension is a common secondary complication due to sodium retention and activation of the RAAS pathway.

10. Are there specific KDIGO targets for these patients?
While KDIGO focuses on CKD management, cystinuria patients should follow the "CKD Prevention" pathway, specifically maintaining blood pressure < 130/80 mmHg and managing proteinuria if present.

Related Clinical Integration

In the clinical management of cystinuria, a multidisciplinary approach is essential for accurate diagnosis, long-term monitoring, and therapeutic intervention. Diagnostic confirmation typically begins with a Urinalysis and a 24-hour urine collection for cystine, which requires a specialized Urine collection container. Patients may also undergo Genetic Testing to identify underlying mutations, while Renal Ultrasound and occasionally a Kidney Biopsy are utilized to assess structural damage or complications. If nephrolithiasis occurs, advanced interventions such as Cholangioscopy (SpyGlass) with Lithotripsy may be indicated. Pharmacological management focuses on increasing cystine solubility through urinary alkalinization using Sodium Bicarbonate / بيكربونات الصوديوم 50mEq/50ml, Citrate Salts (e.g., Potassium Citrate) / أملاح السترات (مثل، سترات البوتاسيوم) Standard, or Potassium Citrate / سترات البوتاسيوم Standard, with efficacy monitored via a [pH meter / جهاز قياس الأس الهيدروجيني (معدات طبية عامة)](https://yemenhealthos.com/ar/clinic/devices/ph-meter-c